Navigation Links
Testing antioxidant drugs is transparent

A study using genetically modified zebrafish to visualize early events involved in development of human atherosclerosis describes an efficient model one that the researchers say offers many applications for testing the potential effectiveness of new antioxidant and dietary therapies.

The research, led by scientists from the University of California, San Diego School of Medicine, has been published online by the Journal of Clinical Investigation, and will appear in print in the December 1 issue of the journal.

Atherosclerosis is a process of lipid deposition and inflammation in the artery walls. Low-density lipoprotein (LDL) that carries "bad" cholesterol in blood is easily oxidized, and oxidized LDL promotes inflammatory responses by vascular cells. Inflamed atherosclerotic plaque can often rupture; this results in a blood clot, obstruction of blood flow to the heart or brain, and heart attack or stroke.

An international team of researchers led by Yury Miller, MD, PhD, of the UCSD Department of Medicine, working with colleagues in Australia, developed an approach to see literally the accumulation of oxidized LDL in genetically modified zebrafish fed a diet high in cholesterol. Because young zebrafish are transparent, the researchers were able to study vascular lipid accumulation, lipid oxidation, and uptake of oxidized LDL by macrophages all in live animals.

To be able to see oxidized LDL, the researchers inserted a gene encoding an antibody that recognizes oxidized LDL, conjugated with green fluorescent protein (GFP), into the zebrafish genome. The antibody, called IK17, was originally cloned from a patient with severe coronary heart disease by the group of scientists led by Joseph L. Witztum, MD, and Sotirios Tsimikas, MD, also of the UCSD Department of Medicine.

The new gene was silent in zebrafish until their tank water was warmed to 99F (37C.) After one hour of this "heat shock," IK17-GFP was produced and eventually bound to its target oxidized LDL in the vascular wall. The green glow of GFP was clearly seen in tiny, live zebrafish under microscope. It was then put back into the fish tank until next picture-taking session.

"Using this technique, we were able to measure the time course of oxidized lipid accumulation in the vascular wall and visualize the effects of treatment with an antioxidant drug, and saw that it reversed the accumulation of oxidized LDL," said the paper's first author Longhou Fang, PhD. "The same therapeutic effect was achieved by switching the zebrafish back to a diet low in cholesterol. We saw the results in just 10 days working with the zebrafish model. A similar experiment in mice took 6 months to complete."

"I see this cholesterol-fed, transgenic zebrafish model as a novel way to study early vascular lipid accumulation and lipoprotein oxidation, the processes that lead to heart disease in humans," said Miller. "Since it is relatively easy and cost-effective to establish and maintain new transgenic zebrafish lines, this offers an in-vivo test for new antioxidants and other drug candidates that could affect development of human atherosclerosis."


Contact: Debra Kain
University of California - San Diego

Related medicine news :

1. New testing method hints at garlics cancer-fighting potential
2. Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis
3. Christine P. Carrington, President of NurseTesting Creative Solutions, Inducted into Cambridge Who's Who
4. New Allergy Testing Available for Patients Allergic to Penicillin: Determining the Presence of Penicillin Allergy is Essential to Patient Care
5. Breast Cancer Patients Often Confused by Genomic Testing
6. Study Results Validate Shape-HF as Simplified, Portable Cardiopulmonary Exercise Testing System
7. San Francisco AIDS Foundation Introduces HIV Testing to Sixth Street
8. Phybridge Inc. Joins the Cisco Developer Network and Completes Cisco Interoperability Verification Testing
9. UAB testing software program to improve safety among older drivers
10. Study Published by Circulation Heart Failure Reinforces Science Behind Shape-HF Cardiopulmonary Exercise Testing Device
11. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
Post Your Comments:
Related Image:
Testing antioxidant drugs is transparent
(Date:10/13/2015)... ... October 13, 2015 , ... Tempe Dental Care, a leading Tempe ... and IV sedation dentistry for more than 5 years. A leading cause ... serious and painful if treatment is not timely. , Sedation dentistry ...
(Date:10/13/2015)... ... 13, 2015 , ... California Southern University has named Dr. ... her Doctor of Nursing Practice from the renowned Johns Hopkins University—comes to CalSouthern ... Dr. McLeod’s long and successful nursing practice included a variety of patient care, ...
(Date:10/13/2015)... ... October 13, 2015 , ... World Patent Marketing , a vertically ... melting invention that helps people in clearing snow away from the streets and driveways. ... at 3.8% per year," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:10/13/2015)... ... 2015 , ... Local Gold’s Gym franchise owner, Bryce Berry, received the Visionary ... who owns and operates Gold's Gym Cheyenne in Cheyenne, Wyoming, received the ... United States. A brand leader in global fitness, Gold’s Gyms are located worldwide. Every ...
(Date:10/13/2015)... ... 13, 2015 , ... According to an ESPN report published on ... teammate accidentally elbowed him in the left eye during the first day of practice ... of a series of setbacks, including a knee injury that has interfered with his ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... MUNICH , October 13, 2015 ... --> World Thrombosis Day Interactive Infographic   ... World Thrombosis Day  to promote vital ... and signs and symptoms. Thrombosis is the formation ... (venous thrombosis) - resulting in venous thromboembolism (VTE) ...
(Date:10/13/2015)... -- XiMo AG ( Lucerne , ... Milpitas, California ) announced today the launch of ... of metathesis chemistry was highlighted by the Nobel Prize ... This industrially-relevant application has been utilized in the production ... and polymers. Georg Fráter , COO of ...
(Date:10/13/2015)... , Oct. 13, 2015  Asterias Biotherapeutics, Inc. ... the UK-based Cell Therapy Catapult to advance development ... allogeneic dendritic cell immunotherapy. Under the agreement, the ... processes for AST-VAC2 to support advanced clinical trials ... --> --> The Cell Therapy ...
Breaking Medicine Technology: